FAUCHIER LAURENT

A/ Présentation des thèmes de recherche

Les travaux effectués ces dernières années témoignent de la pertinence des questions de l’équipe pour le domaine de la cardiologie. On y retrouve des recoupements pour les questions de stratification du risque (avec élaboration d’outils spécifiques, par exemple sous forme de score de risque, ainsi que leur évaluation ou leur validation), du vieillissement des populations avec des pathologies cardiaques posant des questions sur les fins de vie et les modes de décès, d’évaluation des coûts de santé à l’échelle de la population et des rapports bénéfice/risque des thérapeutiques en cardiologie, et de l’optimisation des décisions pour les prise en charge en cardiologie (comprenant d’une part la participation à l’élaboration de documents de synthèse et de recommandations, et d’autre part des études sur l’impact et l’applicabilité des recommandations). 

B/ Publications
. Marijon E, Fauchier L, Le Heuzey J-Y. New antithrombotic drugs and European approval processes. Lancet 2011;378:662–663.
. Marijon E, Le Heuzey J-Y, Fauchier L. Review of novel therapeutics by three regulatory agencies. N Engl J Med 2012;367:1166; author reply 1166-1167.
. Lip GYH, Banerjee A, Lagrenade I, Lane DA, Taillandier S, Fauchier L. Assessing the risk of bleeding in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation project. Circ Arrhythm Electrophysiol 2012;5:941–948.
. Olesen JB, Fauchier L, Lane DA, Taillandier S, Lip GYH. Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest 2012;141:147–153.
. Banerjee A, Fauchier L, Vourc’h P, Andres CR, Taillandier S, Halimi JM, Lip GYH. Renal impairment and ischemic stroke risk assessment in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. J Am Coll Cardiol 2013;61:2079–2087.
. Hanon O, Assayag P, Belmin J, Collet JP, Emeriau JP, Fauchier L, Forette F, Friocourt P, Gentric A, Leclercq C, Komajda M, Le Heuzey JY, French Society of Geriatrics and Gerantology, French Society of Cardiology. Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people. Arch Cardiovasc Dis 2013;106:303–323.
. Hanon O, Assayag P, Belmin J, Collet JP, Emeriau JP, Fauchier L, Forette F, Friocourt P, Gentric A, Leclercq C, Komajda M, Le Heuzey JY, French society of geriatrics and gerontology and the French society of cardiology. [Expert consensus of the French society of geriatrics and gerontology and the French society of cardiology on the management of atrial fibrillation in elderly people]. Gériatrie Psychol Neuropsychiatr Vieil 2013;11:117–143.
. Brunet-Bernard A, Maréchaux S, Fauchier L, Guiot A, Fournet M, Reynaud A, Schnell F, Leclercq C, Mabo P, Donal E. Combined score using clinical, electrocardiographic, and echocardiographic parameters to predict left ventricular remodeling in patients having had cardiac resynchronization therapy six months earlier. Am J Cardiol 2014;113:2045–2051.
. Lip GYH, Haguenoer K, Saint-Etienne C, Fauchier L. Relationship of the SAMe-TT₂R₂ score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest 2014;146:719–726.
. Banerjee A, Fauchier L, Bernard-Brunet A, Clementy N, Lip GYH. Composite risk scores and composite endpoints in the risk prediction of outcomes in anticoagulated patients with atrial fibrillation. The Loire Valley Atrial Fibrillation Project. Thromb Haemost 2014;111:549–556.
. Fauchier L, Angoulvant D, Lip GYH. The SAMe-TT2R2 score and quality of anticoagulation in atrial fibrillation: a simple aid to decision-making on who is suitable (or not) for vitamin K antagonists. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol 2015;17:671–673.
. Fauchier L, Marijon E, Defaye P, Piot O, Sadoul N, Perier M-C, Gras D, Klug D, Algalarrondo V, Bordachar P, Deharo J-C, Leclercq C, Babuty D, Boveda S, DAI-PP Investigators. Effect of age on survival and causes of death after primary prevention implantable cardioverter-defibrillator implantation. Am J Cardiol 2015;115:1415–1422.
. Philippart  R, Brunet-Bernard A, Clementy N, Bourguignon T, Mirza A, Babuty D, Angoulvant D, Lip GY, Fauchier L.  Prognostic value of CHA2DS2-VASc score in patients with 'non-valvular atrial fibrillation' and valvular heart disease: the Loire Valley Atrial Fibrillation Project. Eur Heart J. 2015 Jul 21;36(28):1822-30. doi: 10.1093/eurheartj/ehv163.
. Fauchier  L, Clementy N, Pelade C, Collignon C, Nicolle E, Lip GY. Patients With Ischemic Stroke and Incident Atrial Fibrillation: A Nationwide Cohort Study. Stroke. 2015 Sep;46(9):2432-7. doi: 10.1161/STROKEAHA.115.010270. Epub 2015 Aug 6.
. Fauchier L, Poli D, Olshansky B.The SAMe-TT2R2 score and quality of anticoagulation in AF: Can we predict which patient benefits from anticoagulation? Thromb Haemost. 2015 Oct;114(4):657-9. doi: 10.1160/TH15-06-0518.
. Cotté FE, Chaize G, Gaudin AF, Samson A, Vainchtock A, Fauchier L. Burden of stroke and other cardiovascular complications in patients with atrial fibrillation hospitalized in France. Europace. 2016 Apr;18(4):501-7. doi: 10.1093/europace/euv248.
. Wilkoff BL, Fauchier L, Stiles MK, Morillo CA, Al-Khatib SM, Almendral J, Aguinaga L, Berger RD, Cuesta A, Daubert JP, Dubner S, Ellenbogen KA, Mark Estes NA 3rd, Fenelon G, Garcia FC, Gasparini M, Haines DE, Healey JS, Hurtwitz JL, Keegan R, Kolb C, Kuck KH, Marinskis G, Martinelli M, McGuire M, Molina LG, Okumura K, Proclemer A, Russo AM, Singh JP, Swerdlow CD, Teo WS, Uribe W, Viskin S, Wang CC, Zhang S. 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Heart Rhythm. 2016 Feb;13(2):e50-86. doi: 10.1016/j.hrthm.2015.11.018
. Ancedy Y, Lecoq C, Saint Etienne C, Ivanes F, Angoulvant D, Babuty D, Lip GY, Fauchier L. Antithrombotic management in patients with atrial fibrillation undergoing coronary stent implantation: What is the impact of guideline adherence? Int J Cardiol. 2016 Jan 15;203:987-94. doi: 10.1016/j.ijcard.2015.11.090.
. Diamantopoulos A, Sawyer LM, Lip GY, Witte KK, Reynolds MR, Fauchier L, Thijs V, Brown B, Quiroz Angulo ME, Diener HC. Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke. Int J Stroke. 2016 Apr;11(3):302-12. doi: 10.1177/1747493015620803.
. Fauchier L, Chaize G, Gaudin AF, Vainchtock A, Rushton-Smith SK, Cotté FE. Predictive ability of HAS-BLED, HEMORR2HAGES, and ATRIA bleeding risk scores in patients with atrial fibrillation. A French nationwide cross-sectional study. Int J Cardiol. 2016 Aug 15;217:85-91. doi: 10.1016/j.ijcard.2016.04.173.
. Fauchier L, Clementy N, Bisson A, Ivanes F, Angoulvant D, Babuty D, Lip GY. Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA2DS2-VASc Risk Factor Be Anticoagulated? Stroke. 2016 Jul;47(7):1831-6. doi: 10.1161/STROKEAHA.116.013253.
. Fauchier L, Villejoubert O, Clementy N, Bernard A, Pierre B, Angoulvant D, Ivanes F, Babuty D, Lip GY. Causes of Death and Influencing Factors in Patients with Atrial Fibrillation. Am J Med. 2016 Jul 28. pii: S0002-9343(16)30732-X. doi: 10.1016/j.amjmed.2016.06.045.
. Fauchier L, Lecoq C, Ancedy Y, Stamboul K, Saint Etienne C, Ivanes F, Angoulvant D, Babuty D, Cottin Y, Lip GY. Evaluation of 5 Prognostic Scores for Prediction of Stroke, Thromboembolic and Coronary Events, All-Cause Mortality, and Major Adverse Cardiac Events in Patients With Atrial Fibrillation and Coronary Stenting. Am J Cardiol. 2016 Sep 1;118(5):700-7. doi: 10.1016/j.amjcard.2016.06.018.
. Lip GY, Fauchier L, Freedman SB, Van Gelder I, Natale A, Gianni C, Nattel S, Potpara T, Rienstra M, Tse HF, Lane DA. Atrial fibrillation. Nat Rev Dis Primers. 2016 Mar 31;2:16016. doi: 10.1038/nrdp.2016.16.
. Piccini JP, Fauchier L. Rhythm control in atrial fibrillation. Lancet. 2016 Aug 20;388(10046):829-40.
. Darwiche W, Bejan-Angoulvant T, Angoulvant D, Babuty D, Fauchier L. Risk of myocardial infarction and death in patients with atrial fibrillation treated with dabigatran or vitamin K antagonists. Meta-analysis of observational analyses. Thromb Haemost. 2016 Sep 1;116(5). 

C/ Colloques, conférences et communications

2016
. Congrès Stimudef de Stimulation cardiaque, organisé avec le Groupe de Rythmologie et de Stimulation de la Société Française de Cardiologie, Paris, Mars 2016. Membre du comité d’organisation.

2017
.Congrès Stimudef de Stimulation cardiaque, organisé avec le Groupe de Rythmologie et de Stimulation de la Société Française de Cardiologie, Paris, Mars 2017. Membre du comité d’organisation.
. 19es Journées de Rythmologie, Congrès du Groupe de Rythmologie et de Stimulation de la Société Française de Cardiologie, Avignon, Octobre 2017. Membre du comité d’organisation.

2018
Congrès Stimudef de Stimulation cardiaque, organisé avec le Groupe de Rythmologie et de Stimulation de la Société Française de Cardiologie, Paris, Mars 2018. Membre du comité d’organisation.

2019
Congrès Stimudef de Stimulation cardiaque, organisé avec le Groupe de Rythmologie et de Stimulation de la Société Française de Cardiologie, Paris, Mars 2019. Membre du comité d’organisation et vice président du congrès.
. 20es Journées de Rythmologie, Congrès du Groupe de Rythmologie et de Stimulation de la Société Française de Cardiologie, Avignon, Octobre 2019. Membre du comité d’organisation et vice président du congrès

D/ Recherches et interventions

. Expert pour Archives des Maladies du Coeur et des Vaisseaux, Annales de Cardiologie et d’Angéiologie, The American Journal of Cardiology, American Journal of Hypertension, American Journal of Physiology - Heart and Circulatory Physiology, Circulation, Coronary Artery Disease, Critical Care Medicine, Europace, Journal of the American College of Cardiology, Journal of Applied Physiology, European Heart Journal, Heart, Obesity Research, The Lancet, Thrombosis Haemostas
 

1. Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S, van Eickels M, Turpie AGG, XANTUS Investigators. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. 2016;37:1145–1153.
2. Fauchier L, Lecoq C, Clementy N, Bernard A, Angoulvant D, Ivanes F, Babuty D, Lip GYH. Oral Anticoagulation and the Risk of Stroke or Death in Patients With Atrial Fibrillation and One Additional Stroke Risk Factor: The Loire Valley Atrial Fibrillation Project. Chest. 2016;149:960–968.
3. Ancedy Y, Lecoq C, Saint Etienne C, Ivanes F, Angoulvant D, Babuty D, Lip GYH, Fauchier L. Antithrombotic management in patients with atrial fibrillation undergoing coronary stent implantation: What is the impact of guideline adherence? Int J Cardiol. 2016;203:987–994.
4. Ascoeta MS, Marijon E, Defaye P, Klug D, Beganton F, Perier M-C, Gras D, Algalarrondo V, Deharo J-C, Leclercq C, Fauchier L, Babuty D, Bordachar P, Sadoul N, Boveda S, Piot O, DAI-PP Investigators. Impact of early complications on outcomes in patients with implantable cardioverter-defibrillator for primary prevention. Heart Rhythm. 2016;13:1045–1051.
5. Diamantopoulos A, Sawyer LM, Lip GY, Witte KK, Reynolds MR, Fauchier L, Thijs V, Brown B, Quiroz Angulo ME, Diener H-C. Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke. Int J Stroke Off J Int Stroke Soc. 2016;11:302–312.
6. Darwiche W, Bejan-Angoulvant T, Dievart F, Babuty D, Angoulvant D, Fauchier L. Bleeding risk in patients treated with dabigatran or vitamin K antagonist for atrial fibrillation: A meta analysis of adjusted analysis in routine practice settings. Int J Cardiol. 2016;206:89–92.
7. Philippart R, Brunet-Bernard A, Clementy N, Bourguignon T, Mirza A, Angoulvant D, Babuty D, Lip GYH, Fauchier L. CHA2DS2-VASc Score for Predicting Stroke and Thromboembolism in Patients With AF and Biological Valve Prosthesis. J Am Coll Cardiol. 2016;67:343–344.
8. Philippart R, Brunet-Bernard A, Clementy N, Bourguignon T, Mirza A, Angoulvant D, Babuty D, Lip GYH, Fauchier L. Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project. Thromb Haemost. 2016;115:1056–1063.
9. Providência R, Marijon E, Lambiase PD, Bouzeman A, Defaye P, Klug D, Amet D, Perier M-C, Gras D, Algalarrondo V, Deharo J-C, Leclercq C, Fauchier L, Babuty D, Bordachar P, Sadoul N, Piot O, Boveda S. Primary Prevention Implantable Cardioverter Defibrillator (ICD) Therapy in Women-Data From a Multicenter French Registry. J Am Heart Assoc. 2016;5.
10. Wilkoff BL, Fauchier L, Stiles MK, Morillo CA, Al-Khatib SM, Almendral J, Aguinaga L, Berger RD, Cuesta A, Daubert JP, Dubner S, Ellenbogen KA, Estes NAM, Fenelon G, Garcia FC, Gasparini M, Haines DE, Healey JS, Hurtwitz JL, Keegan R, Kolb C, Kuck K-H, Marinskis G, Martinelli M, McGuire M, Molina LG, Okumura K, Proclemer A, Russo AM, Singh JP, Swerdlow CD, Teo WS, Uribe W, Viskin S, Wang C-C, Zhang S. 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. J Arrhythmia. 2016;32:1–28.
11. Fauchier L, Laborie G, Clementy N, Babuty D. Beta-blockers or Digoxin for Atrial Fibrillation and Heart Failure? Card Fail Rev. 2016;2:35–39.
12. Pericart L, Fauchier L, Bourguignon T, Bernard L, Angoulvant D, Delahaye F, Babuty D, Bernard A. Long-Term Outcome and Valve Surgery for Infective Endocarditis in the Systematic Analysis of a Community Study. Ann Thorac Surg. 2016;102:496–504.
13. Lip GYH, Fauchier L, Freedman SB, Van Gelder I, Natale A, Gianni C, Nattel S, Potpara T, Rienstra M, Tse H-F, Lane DA. Atrial fibrillation. Nat Rev Dis Primer. 2016;2:16016.
14. Fauchier L, Chaize G, Gaudin A-F, Vainchtock A, Rushton-Smith SK, Cotté F-E. Predictive ability of HAS-BLED, HEMORR2HAGES, and ATRIA bleeding risk scores in patients with atrial fibrillation. A French nationwide cross-sectional study. Int J Cardiol. 2016;217:85–91.
15. Fauchier L, Clementy N, Bisson A, Ivanes F, Angoulvant D, Babuty D, Lip GYH. Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA2DS2-VASc Risk Factor Be Anticoagulated? Stroke. 2016;47:1831–1836.
16. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener H-C, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P, ESC Scientific Document Group. Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. Eur Heart J. 2017;38:2137–2149.
17. Garcia B, Clementy N, Benhenda N, Pierre B, Babuty D, Olshansky B, Fauchier L. Mortality After Atrioventricular Nodal Radiofrequency Catheter Ablation With Permanent Ventricular Pacing in Atrial Fibrillation: Outcomes From a Controlled Nonrandomized Study. Circ Arrhythm Electrophysiol. 2016;9.
18. Perrin T, Mechulan A, Boveda S, Beganton F, Defaye P, Sadoul N, Piot O, Klug D, Gras D, Perier M-C, Algalarrondo V, Bordachar P, Babuty D, Fauchier L, Leclercq C, Marijon E, Deharo J-C, DAI-PP Investigators. Does defibrillation testing influence outcomes after CRT-D implantation? A cause-of-death analysis from the DAI-PP study. Int J Cardiol. 2016;221:951–956.
19. Fauchier L, Lecoq C, Ancedy Y, Stamboul K, Saint Etienne C, Ivanes F, Angoulvant D, Babuty D, Cottin Y, Lip GYH. Evaluation of 5 Prognostic Scores for Prediction of Stroke, Thromboembolic and Coronary Events, All-Cause Mortality, and Major Adverse Cardiac Events in Patients With Atrial Fibrillation and Coronary Stenting. Am J Cardiol. 2016;118:700–707.
20. Fauchier L, Villejoubert O, Clementy N, Bernard A, Pierre B, Angoulvant D, Ivanes F, Babuty D, Lip GYH. Causes of Death and Influencing Factors in Patients with Atrial Fibrillation. Am J Med. 2016;129:1278–1287.
21. Fauchier L, Bisson A, Lip GYH. Response by Fauchier et al to Letter Regarding Article, “Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA2DS2-VASc Risk Factor Be Anticoagulated?” Stroke. 2016;47:e239.
22. Piccini JP, Fauchier L. Rhythm control in atrial fibrillation. Lancet Lond Engl. 2016;388:829–840.
23. Providência R, Boveda S, Defaye P, Segal O, Algalarrondo V, Sadoul N, Lambiase P, Piot O, Klug D, Perier M-C, Bouzeman A, Barra S, Bories M-C, Gras D, Fauchier L, Bordachar P, Babuty D, Deharo J-C, Leclercq C, Marijon E, DAI-PP Investigators. Outcome of Primary Prevention Implantable Cardioverter Defibrillator Therapy According to New York Heart Association Functional Classification. Am J Cardiol. 2016;118:1225–1232.
24. Fauchier L, Ruiz-Nodar JM, Valdés M, Angoulvant D, Lip GYH, Marín F. Is oral anticoagulation needed in patients with atrial fibrillation and stent implantation at low-moderate risk of stroke? Eur J Intern Med. 2016;35:e9–e10.
25. Darwiche W, Bejan-Angoulvant T, Angoulvant D, Babuty D, Fauchier L. Risk of myocardial infarction and death in patients with atrial fibrillation treated with dabigatran or vitamin K antagonists. Meta-analysis of observational analyses. Thromb Haemost. 2016;116:1150–1158.
26. Fauchier L, Alonso C, Anselme F, Blangy H, Bordachar P, Boveda S, Clementy N, Defaye P, Deharo J-C, Friocourt P, Gras D, Halimi F, Klug D, Mansourati J, Obadia B, Pasquié J-L, Pavin D, Sadoul N, Taieb J, Piot O, Hanon O. Position paper for management of elderly patients with pacemakers and implantable cardiac defibrillators: Groupe de Rythmologie et Stimulation Cardiaque de la Société Française de Cardiologie and Société Française de Gériatrie et Gérontologie. Arch Cardiovasc Dis. 2016;109:563–585.
27. Fauchier L, Alonso C, Anselme F, Blangy H, Bordachar P, Boveda S, Clementy N, Defaye P, Deharo J-C, Friocourt P, Gras D, Halimi F, Klug D, Mansourati J, Obadia B, Pasquié J-L, Pavin D, Sadoul N, Taieb J, Piot O, Hanon O. Position paper for management of elderly patients with pacemakers and implantable cardiac defibrillators Groupe de rythmologie et stimulation cardiaque de la Société française de cardiologie et Société française de gériatrie et gérontologie. Geriatr Psychol Neuropsychiatr Vieil. 2016;14:239–264.
28. Clementy N, Benhenda N, Piver E, Pierre B, Bernard A, Fauchier L, Pages J-C, Babuty D. Serum Galectin-3 Levels Predict Recurrences after Ablation of Atrial Fibrillation. Sci Rep. 2016;6:34357.
29. Fauchier L, Clementy N, Bisson A, Stamboul K, Ivanes F, Angoulvant D, Babuty D, Lip GYH. Prognosis in patients with atrial fibrillation and a presumed “temporary cause” in a community-based cohort study. Clin Res Cardiol Off J Ger Card Soc. 2017;106:202–210.
30. Reek S, Burri H, Roberts PR, Perings C, Epstein AE, Klein HU, EHRA Scientific Documents Committee (as external reviewers):, Lip G, Gorenek B, Sticherling C, Fauchier L, Goette A, Jung W, Vos MA, Brignole M, Elsner C, Dan G-A, Marin F, Boriani G, Lane D, Blomström-Lundqvist C, Savelieva I. The wearable cardioverter-defibrillator: current technology and evolving indications. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2017;19:335–345.
31. Gorenek Chair B, Pelliccia Co-Chair A, Benjamin EJ, Boriani G, Crijns HJ, Fogel RI, Van Gelder IC, Halle M, Kudaiberdieva G, Lane DA, Bjerregaard Larsen T, Lip GYH, Løchen M-L, Marin F, Niebauer J, Sanders P, Tokgozoglu L, Vos MA, Van Wagoner DR, Document reviewers:, Fauchier L, Savelieva I, Goette A, Agewall S, Chiang C-E, Figueiredo M, Stiles M, Dickfeld T, Patton K, Piepoli M, Corra U, Manuel Marques-Vidal P, Faggiano P, Schmid J-P, Abreu A. European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). Eur J Prev Cardiol. 2017;24:4–40.
32. Fauchier L, Bisson A, Clementy N. Prognosis in Familial Atrial Fibrillation. J Am Heart Assoc. 2016;5.
33. Potpara TS, Dagres N, Mujović N, Vasić D, Ašanin M, Nedeljkovic M, Marin F, Fauchier L, Blomstrom-Lundqvist C, Lip GYH. Decision-Making in Clinical Practice: Oral Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation and a Single Additional Stroke Risk Factor. Adv Ther. 2017;34:357–377.
34. Clementy N, Challal F, Marijon E, Boveda S, Defaye P, Leclercq C, Deharo J-C, Sadoul N, Klug D, Piot O, Gras D, Bordachar P, Algalarrondo V, Fauchier L, Babuty D, DAI-PP Investigators. Very high rate programming in primary prevention patients with reduced ejection fraction implanted with a defibrillator: Results from a large multicenter controlled study. Heart Rhythm. 2017;14:211–217.
35. Fauchier L, Bisson A, Clementy N. ICD Implantation in Patients with Nonischemic Heart Failure. N Engl J Med. 2017;376:89–90.
36. Amara N, Boveda S, Defaye P, Klug D, Treguer F, Amet D, Perier M-C, Gras D, Algalarrondo V, Bouzeman A, Piot O, Deharo J-C, Fauchier L, Babuty D, Bordachar P, Sadoul N, Marijon E, Leclercq C, DAI-PP Investigators. Implantable cardioverter-defibrillator therapy among patients with non-ischaemic vs. ischaemic cardiomyopathy for primary prevention of sudden cardiac death. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2018;20:65–72.
37. Gorenek B, Pelliccia A, Benjamin EJ, Boriani G, Crijns HJ, Fogel RI, Van Gelder IC, Halle M, Kudaiberdieva G, Lane DA, Larsen TB, Lip GYH, Løchen M-L, Marín F, Niebauer J, Sanders P, Tokgozoglu L, Vos MA, Van Wagoner DR, Fauchier L, Savelieva I, Goette A, Agewall S, Chiang C-E, Figueiredo M, Stiles M, Dickfeld T, Patton K, Piepoli M, Corra U, Marques-Vidal PM, Faggiano P, Schmid J-P, Abreu A. European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2017;19:190–225.
38. Boveda S, Narayanan K, Jacob S, Providencia R, Algalarrondo V, Bouzeman A, Beganton F, Defaye P, Perier M-C, Sadoul N, Piot O, Klug D, Gras D, Fauchier L, Bordachar P, Babuty D, Deharo J-C, Leclercq C, Marijon E, DAI-PP Investigators. Temporal Trends Over a Decade of Defibrillator Therapy for Primary Prevention in Community Practice. J Cardiovasc Electrophysiol. 2017;28:666–673.
39. Defaye P, Boveda S, Klug D, Beganton F, Piot O, Narayanan K, Périer M-C, Gras D, Fauchier L, Bordachar P, Algalarrondo V, Babuty D, Deharo J-C, Leclercq C, Marijon E, Sadoul N, DAI-PP Investigators. Dual- vs. single-chamber defibrillators for primary prevention of sudden cardiac death: long-term follow-up of the Défibrillateur Automatique Implantable-Prévention Primaire registry. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2017;19:1478–1484.

40. Pericart L, Bernard A, Bourguignon T, Bernard L, Angoulvant D, Clementy N, Babuty D, Fauchier L. Comparison of Outcome of Possible Versus Definite Infective Endocarditis Involving Native Heart Valves. Am J Cardiol. 2017;119:1854–1861.
41. Bernard A, Menet A, Marechaux S, Fournet M, Schnell F, Guyomar Y, Leclercq C, Mabo P, Fauchier L, Donal E. Predicting Clinical and Echocardiographic Response After Cardiac Resynchronization Therapy With a Score Combining Clinical, Electrocardiographic, and Echocardiographic Parameters. Am J Cardiol. 2017;119:1797–1802.
42. Fauchier L, Pericart L, Bourguignon T, Bernard L, Clementy N, Angoulvant D, Babuty D, Bernard A. Prediction of Systemic Septic Embolism in Patients With Left-Sided Infective Endocarditis. J Am Coll Cardiol. 2017;69:1992–1993.
43. Freedman B, Camm J, Calkins H, Healey JS, Rosenqvist M, Wang J, Albert CM, Anderson CS, Antoniou S, Benjamin EJ, Boriani G, Brachmann J, Brandes A, Chao T-F, Conen D, Engdahl J, Fauchier L, Fitzmaurice DA, Friberg L, Gersh BJ, Gladstone DJ, Glotzer TV, Gwynne K, Hankey GJ, Harbison J, Hillis GS, Hills MT, Kamel H, Kirchhof P, Kowey PR, Krieger D, Lee VWY, Levin L-Å, Lip GYH, Lobban T, Lowres N, Mairesse GH, Martinez C, Neubeck L, Orchard J, Piccini JP, Poppe K, Potpara TS, Puererfellner H, Rienstra M, Sandhu RK, Schnabel RB, Siu C-W, Steinhubl S, Svendsen JH, Svennberg E, Themistoclakis S, Tieleman RG, Turakhia MP, Tveit A, Uittenbogaart SB, Van Gelder IC, Verma A, Wachter R, Yan BP, AF-Screen Collaborators. Screening for Atrial Fibrillation: A Report of the AF-SCREEN International Collaboration. Circulation. 2017;135:1851–1867.
44. Bisson A, Angoulvant D, Philippart R, Clementy N, Babuty D, Fauchier L. Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation. Adv Ther. 2017;34:1283–1290.
45. Deng H, Bai Y, Shantsila A, Fauchier L, Potpara TS, Lip GYH. Clinical scores for outcomes of rhythm control or arrhythmia progression in patients with atrial fibrillation: a systematic review. Clin Res Cardiol Off J Ger Card Soc. 2017;106:813–823.
46. Clementy N, Laborie G, Pierre B, Benhenda N, Babuty D, Fauchier L. Three-dimensional interlead distance predicts response and outcomes after cardiac resynchronization therapy. Arch Cardiovasc Dis. 2017;110:590–598.
47. Escande W, Boveda S, Defaye P, Leclercq C, Sadoul N, Perier M-C, Deharo J-C, Fauchier L, Marijon E, Piot O, DAI-PP Investigators. Outcomes in Guideline-Based Versus Off-Guideline Primary Prevention Implantable Cardioverter-Defibrillator Recipients. J Am Coll Cardiol. 2017;70:1302–1303.
48. Bisson A, Clementy N, Bodin A, Angoulvant D, Babuty D, Lip GYH, Fauchier L. Relationship of Preexisting Cardiovascular Comorbidities to Newly Diagnosed Atrial Fibrillation After Ischemic Stroke. Stroke. 2017;48:2878–2880.
49. Lip GYH, Coca A, Kahan T, Boriani G, Manolis AS, Olsen MH, Oto A, Potpara TS, Steffel J, Marín F, de Oliveira Figueiredo MJ, de Simone G, Tzou WS, Chiang C-E, Williams B, Reviewers:, Dan G-A, Gorenek B, Fauchier L, Savelieva I, Hatala R, van Gelder I, Brguljan-Hitij J, Erdine S, Lovic D, Kim Y-H, Salinas-Arce J, Field M. Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2017;19:891–911.

60. Fauchier L, Bisson A, Genet T. Antiplatelet therapy, vitamin K antagonist and low time in therapeutic range in patients with atrial fibrillation: Highway to bleed. Int J Cardiol. 2018;252:110–111.
61. Bisson A, Bodin A, Clementy N, Babuty D, Lip GYH, Fauchier L. Prediction of Incident Atrial Fibrillation According to Gender in Patients With Ischemic Stroke From a Nationwide Cohort. Am J Cardiol. 2018;121:437–444.
62. Fauchier L, Bisson A, Angoulvant D. Rivaroxaban in Stable Cardiovascular Disease. N Engl J Med. 2018;378:395.
63. Collings S-L, Vannier-Moreau V, Johnson ME, Stynes G, Lefèvre C, Maguire A, Asmar J, Bizouard G, Duhot D, Mouquet F, Fauchier L. Initiation and continuation of oral anticoagulant prescriptions for stroke prevention in non-valvular atrial fibrillation: A cohort study in primary care in France. Arch Cardiovasc Dis. 2018;111:370–379.
64. Bejan-Angoulvant T, Genet T, Vrignaud L, Angoulvant D, Fauchier L. Three case reports of involuntary muscular movements as adverse reactions to sacubitril/valsartan. Br J Clin Pharmacol. 2018;84:1072–1074.
65. Bisson A, Bodin A, Clementy N, Bernard A, Babuty D, Lip GYH, Fauchier L. Stroke, thromboembolism and bleeding in patients with atrial fibrillation according to the EHRA valvular heart disease classification. Int J Cardiol. 2018;260:93–98.
66. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbüchel H, ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39:1330–1393.
67. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Georg Haeusler K, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbüchel H, ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2018;20:1231–1242.
68. Dagres N, Chao T-F, Fenelon G, Aguinaga L, Benhayon D, Benjamin EJ, Bunch TJ, Chen LY, Chen S-A, Darrieux F, de Paola A, Fauchier L, Goette A, Kalman J, Kalra L, Kim Y-H, Lane DA, Lip GYH, Lubitz SA, Márquez MF, Potpara T, Pozzer DL, Ruskin JN, Savelieva I, Teo WS, Tse H-F, Verma A, Zhang S, Chung MK, ESC Scientific Document Group. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice? Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2018;20:1399–1421.
69. Dagres N, Chao T-F, Fenelon G, Aguinaga L, Benhayon D, Benjamin EJ, Bunch TJ, Chen LY, Chen S-A, Darrieux F, de Paola A, Fauchier L, Goette A, Kalman J, Kalra L, Kim Y-H, Lane DA, Lip GYH, Lubitz SA, Márquez MF, Potpara T, Pozzer DL, Ruskin JN, Savelieva I, Teo WS, Tse H-F, Verma A, Zhang S, Chung MK. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice? Heart Rhythm. 2018;15:e37–e60.

70. Gorenek B, Boriani G, Dan G-A, Fauchier L, Fenelon G, Huang H, Kudaiberdieva G, Lip GYH, Mahajan R, Potpara T, Ramirez JD, Vos MA, Marin F, ESC Scientific Document Group. European Heart Rhythm Association (EHRA) position paper on arrhythmia management and device therapies in endocrine disorders, endorsed by Asia Pacific Heart Rhythm Society (APHRS) and Latin American Heart Rhythm Society (LAHRS). Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2018;20:895–896.
71. Bongiorni MG, Burri H, Deharo JC, Starck C, Kennergren C, Saghy L, Rao A, Tascini C, Lever N, Kutarski A, Fernandez Lozano I, Strathmore N, Costa R, Epstein L, Love C, Blomstrom-Lundqvist C, ESC Scientific Document Group. 2018 EHRA expert consensus statement on lead extraction: recommendations on definitions, endpoints, research trial design, and data collection requirements for clinical scientific studies and registries: endorsed by APHRS/HRS/LAHRS. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2018;20:1217.
72. Clementy N, Piver E, Bisson A, Andre C, Bernard A, Pierre B, Fauchier L, Babuty D. Galectin-3 in Atrial Fibrillation: Mechanisms and Therapeutic Implications. Int J Mol Sci. 2018;19.
73. Bourguignon T, Bernard A, Fauchier L. Risk of Thromboembolic Events without Oral Anticoagulation at 90 Days after Surgical Aortic Valve Replacement with a Bioprosthesis. Thromb Haemost. 2018;118:945–947.
74. Fauchier L, Cinaud A, Brigadeau F, Lepillier A, Pierre B, Abbey S, Fatemi M, Franceschi F, Guedeney P, Jacon P, Paziaud O, Venier S, Deharo JC, Gras D, Klug D, Mansourati J, Montalescot G, Piot O, Defaye P. Device-Related Thrombosis After Percutaneous Left Atrial Appendage Occlusion for Atrial Fibrillation. J Am Coll Cardiol. 2018;71:1528–1536.
75. Providencia R, Marijon E, Barra S, Reitan C, Breitenstein A, Defaye P, Papageorgiou N, Duehmke R, Winnik S, Ang R, Klug D, Gras D, Oezkartal T, Segal OR, Deharo J-C, Leclercq C, Lambiase PD, Fauchier L, Bordachar P, Steffel J, Sadoul N, Piot O, Borgquist R, Agarwal S, Chow A, Boveda S, DAI-PP Investigators. Usefulness of a clinical risk score to predict the response to cardiac resynchronization therapy. Int J Cardiol. 2018;260:82–87.
76. Bisson A, Bodin A, Fauchier L. Why and how to screen for atrial fibrillation. Heart Br Card Soc. 2018;104:1474–1475.
77. Fauchier L, Bisson A, Clementy N, Vourc’h P, Angoulvant D, Babuty D, Halimi JM, Lip GYH. Changes in glomerular filtration rate and outcomes in patients with atrial fibrillation. Am Heart J. 2018;198:39–45.
78. Dagres N, Chao T-F, Fenelon G, Aguinaga L, Benhayon D, Benjamin EJ, Bunch TJ, Chen LY, Chen S-A, Darrieux F, de Paola A, Fauchier L, Goette A, Kalman J, Kalra L, Kim Y-H, Lane DA, Lip GYH, Lubitz SA, Márquez MF, Potpara T, Pozzer DL, Ruskin JN, Savelieva I, Teo WS, Tse H-F, Verma A, Zhang S, Chung MK, Bautista-Vargas W-F, Chiang C-E, Cuesta A, Dan G-A, Frankel DS, Guo Y, Hatala R, Lee YS, Murakawa Y, Pellegrini CN, Pinho C, Milan DJ, Morin DP, Nadalin E, Ntaios G, Prabhu MA, Proietti M, Rivard L, Valentino M, Shantsila A. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: What is the best practice? J Arrhythmia. 2018;34:99–123.
79. Clementy N, Bisson A, Challal F, Andre C, Pierre B, Fauchier L, Babuty D. Nonsustained Ventricular Tachycardia at the Time of Implantation Predicts Appropriate Therapies on Rapid Ventricular Arrhythmia in Primary Prevention Patients With Nonischemic Cardiomyopathy: Results From the Very-High-Rate Registry. JACC Clin Electrophysiol. 2017;3:1338–1339.

80. Boriani G, Fauchier L, Aguinaga L, Beattie JM, Blomstrom Lundqvist C, Cohen A, Dan G-A, Genovesi S, Israel C, Joung B, Kalarus Z, Lampert R, Malavasi VL, Mansourati J, Mont L, Potpara T, Thornton A, Lip GYH, ESC Scientific Document Group. European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS). Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2019;21:7–8.
81. Linde C, Bongiorni MG, Birgersdotter-Green U, Curtis AB, Deisenhofer I, Furokawa T, Gillis AM, Haugaa KH, Lip GYH, Van Gelder I, Malik M, Poole J, Potpara T, Savelieva I, Sarkozy A, ESC Scientific Document Group. Sex differences in cardiac arrhythmia: a consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific Heart Rhythm Society. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2018;20:1565–1565ao.
82. Clementy N, Fourquet A, Andre C, Bisson A, Pierre B, Fauchier L, Babuty D, Angoulvant D. Benefits of an early management of palpitations. Medicine (Baltimore). 2018;97:e11466.
83. Fauchier L, Cinaud A, Brigadeau F, Lepillier A, Defaye P. Reply: Device-Related Thrombus After Percutaneous Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2018;72:474–475.
84. Lip GYH, Collet J-P, Haude M, Byrne R, Chung EH, Fauchier L, Halvorsen S, Lau D, Lopez-Cabanillas N, Lettino M, Marin F, Obel I, Rubboli A, Storey RF, Valgimigli M, Huber K, ESC Scientific Document Group. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2019;21:192–193.
85. Guenancia C, Toucas C, Fauchier L, Stamboul K, Garnier F, Mouhat B, Sagnard A, Lorgis L, Zeller M, Cottin Y. High rate of recurrence at long-term follow-up after new-onset atrial fibrillation during acute myocardial infarction. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2018;20:e179–e188.
86. Clementy N, Garcia B, André C, Bisson A, Benhenda N, Pierre B, Bernard A, Fauchier L, Piver E, Babuty D. Galectin-3 level predicts response to ablation and outcomes in patients with persistent atrial fibrillation and systolic heart failure. PloS One. 2018;13:e0201517.
87. Dallongeville J, Sacher F, Bouée S, Emery C, Bureau I, Gourmelen J, Fauchier L. Xafran, a drug utilization study of rivaroxaban in stroke prevention in atrial fibrillation in France using a claim database. Therapie. 2018;73:449–460.
88. Algalarrondo V, Perault R, Bories M-C, Narayanan K, Garcia R, Combes N, Perier M-C, Defaye P, Sadoul N, Gras D, Klug D, Bordachar P, Fauchier L, Deharo J-C, Leclercq C, Boveda S, Marijon E, Babuty D, DAI-PP investigators. Prophylactic implantable cardioverter defibrillators for primary prevention: From implantation to heart transplantation. Arch Cardiovasc Dis. 2018;111:758–765.
89. Zannad F, Anker SD, Byra WM, Cleland JGF, Fu M, Gheorghiade M, Lam CSP, Mehra MR, Neaton JD, Nessel CC, Spiro TE, van Veldhuisen DJ, Greenberg B, COMMANDER HF Investigators. Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. N Engl J Med. 2018;379:1332–1342.

90. Maury P, Defaye P, Klug D, Alonso C, Anselme F, Fauchier L, Gandjbakhch E, Gras D, Hermida J-S, Laurent G, Mansourati J, Marijon E, Sacher F, Taieb J, Boveda S, Piot O, Sadoul N, Working Group of Pacing, Electrophysiology of the French Society of Cardiology. Position paper concerning the competence, performance and environment required in the practice of complex ablation procedures. Arch Cardiovasc Dis. 2019;112:67–73.
91. Briere J-B, Bowrin K, Coleman C, Fauchier L, Levy P, Folkerts K, Toumi M, Taieb V, Millier A, Wu O. Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review. Expert Rev Pharmacoecon Outcomes Res. 2019;19:27–36.
92. Chao T-F, Fauchier L. Stroke prevention in patients with atrial flutter: many questions still unanswered. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2019;21:186–187.
93. Fauchier L, Bisson A, Clementy N. Alcohol and Cardiac Structure: Less Is Better. J Am Coll Cardiol. 2018;72:1463–1465.
94. Bisson A, Pucheux J, Andre C, Bernard A, Pierre B, Babuty D, Fauchier L, Clementy N. Localization of Left Ventricular Lead Electrodes in Relation to Myocardial Scar in Patients Undergoing Cardiac Resynchronization Therapy. J Am Heart Assoc. 2018;7:e009502.
95. Andre C, Piver E, Perault R, Bisson A, Pucheux J, Vermes E, Pierre B, Fauchier L, Babuty D, Clementy N. Galectin-3 predicts response and outcomes after cardiac resynchronization therapy. J Transl Med. 2018;16:299.
96. Fauchier L, Cinaud A, Brigadeau F, Lepillier A, Pierre B, Gras D, Mansourati J, Deharo JC, Montalescot G, Defaye P. Left Atrial Appendage Closure in Atrial Fibrillation. J Am Coll Cardiol. 2018;72:2806–2807.
97. Fauchier L, Bodin A, Bisson A. Editorial commentary: The CHA2DS2VASc score and its black and white items. Trends Cardiovasc Med. 2019;29:392–393.
98. Clementy N, Ancedy Y, Bisson A, Andre C, Pierre B, Fauchier L, Babuty D. Distal-to-proximal delay for ablation of premature ventricular contractions. J Cardiovasc Electrophysiol. 2019;30:205–211.
99. Fauchier L, Clementy N, Bisson A. Wearable Cardioverter–Defibrillator after Myocardial Infarction. N Engl J Med. 2019;380:600.

100. Coleman CI, Briere J-B, Fauchier L, Levy P, Bowrin K, Toumi M, Millier A, Taieb V, Wu O. Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation. J Mark Access Health Policy. 2019;7:1574541.
101. Bisson A, Bernard A, Bodin A, Clementy N, Babuty D, Lip GYH, Fauchier L. Stroke and Thromboembolism in Patients With Atrial Fibrillation and Mitral Regurgitation. Circ Arrhythm Electrophysiol. 2019;12:e006990.
102. Arnar DO, Mairesse GH, Boriani G, Calkins H, Chin A, Coats A, Deharo J-C, Svendsen JH, Heidbüchel H, Isa R, Kalman JM, Lane DA, Louw R, Lip GYH, Maury P, Potpara T, Sacher F, Sanders P, Varma N, Fauchier L, ESC Scientific Document Group, EHRA Scientific Documents Committee. Management of asymptomatic arrhythmias: a European Heart Rhythm Association (EHRA) consensus document, endorsed by the Heart Failure Association (HFA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin America Heart Rhythm Society (LAHRS). Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2019;
103. Goette A, Auricchio A, Boriani G, Braunschweig F, Terradellas JB, Burri H, Camm AJ, Crijns H, Dagres N, Deharo J-C, Dobrev D, Hatala R, Hindricks G, Hohnloser SH, Leclercq C, Lewalter T, Lip GYH, Merino JL, Mont L, Prinzen F, Proclemer A, Pürerfellner H, Savelieva I, Schilling R, Steffel J, van Gelder IC, Zeppenfeld K, Zupan I, Heidbüchel H, ESC Scientific Document Group. EHRA White Paper: knowledge gaps in arrhythmia management-status 2019. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2019;21:993–994.
104. Zakine C, Garcia R, Narayanan K, Gandjbakhch E, Algalarrondo V, Lellouche N, Perier M-C, Fauchier L, Gras D, Bordachar P, Piot O, Babuty D, Sadoul N, Defaye P, Deharo J-C, Klug D, Leclercq C, Extramiana F, Boveda S, Marijon E. Prophylactic implantable cardioverter-defibrillator in the very elderly. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2019;21:1063–1069.
105. Maury P, Defaye P, Klug D, Alonso C, Anselme F, Fauchier L, Gandjbakhch E, Gras D, Hermida J-S, Laurent G, Mansourati J, Marijon E, Sacher F, Taieb J, Boveda S, Piot O, Sadoul N, Working Group on Pacing, Electrophysiology of the French Society of Cardiology. Reply to the letter about the position paper concerning the competence, performance and environment required in the practice of complex ablation procedures. Arch Cardiovasc Dis. 2019;112:290–291.
106. Boriani G, Proietti M, Laroche C, Fauchier L, Marin F, Nabauer M, Potpara T, Dan G-A, Kalarus Z, Tavazzi L, Maggioni AP, Lip GYH, EORP-AF Long-Term General Registry Investigators. Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2019;21:1013–1022.
107. Gras M, Pucheux J, Bisson A, Fauchier L, Babuty D, Clementy N. End-of-service management of leadless cardiac pacemakers: a case report. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2019;21:1245.
108. Barra S, Duehmke R, Providência R, Narayanan K, Reitan C, Roubicek T, Polasek R, Chow A, Defaye P, Fauchier L, Piot O, Deharo J-C, Sadoul N, Klug D, Garcia R, Dockrill S, Virdee M, Pettit S, Agarwal S, Borgquist R, Marijon E, Boveda S. Very long-term survival and late sudden cardiac death in cardiac resynchronization therapy patients. Eur Heart J. 2019;40:2121–2127.
109. Stiles MK, Fauchier L, Morillo CA, Wilkoff BL, ESC Scientific Document Group. 2019 HRS/EHRA/APHRS/LAHRS focused update to 2015 expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2019;21:1442–1443.

110. Stiles MK, Fauchier L, Morillo CA, Wilkoff BL. 2019 HRS/EHRA/APHRS/LAHRS focused update to 2015 expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Heart Rhythm. 2020;17:e220–e228.
111. Fauchier L, Cinaud A, Brigadeau F, Lepillier A, Pierre B, Gras D, Mansourati J, Deharo JC, Montalescot G, Defaye P. Major Adverse Events With Percutaneous Left Atrial Appendage Closure in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2019;73:2638–2640.
112. Beyer-Westendorf J, Camm AJ, Fox KAA, Le Heuzey J-Y, Haas S, Turpie AGG, Virdone S, Kakkar AK, RIVER Registry Investigators. International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER). Thromb J. 2019;17:7.
113. Li Y-G, Bisson A, Bodin A, Herbert J, Grammatico-Guillon L, Joung B, Wang Y-T, Lip GYH, Fauchier L. C2 HEST Score and Prediction of Incident Atrial Fibrillation in Poststroke Patients: A French Nationwide Study. J Am Heart Assoc. 2019;8:e012546.
114. Stiles MK, Fauchier L, Morillo CA, Wilkoff BL. 2019 HRS/EHRA/APHRS/LAHRS focused update to 2015 expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. J Arrhythmia. 2019;35:485–493.
115. Bodin A, Bisson A, Andre C, Pierre B, Fauchier L, Babuty D, Clementy N. Multisite pacing via a quadripolar lead for cardiac resynchronization therapy. J Interv Card Electrophysiol Int J Arrhythm Pacing. 2019;56:117–125.

117. Blin P, Fauchier L, Dureau-Pournin C, Sacher F, Dallongeville J, Bernard M-A, Lassalle R, Droz-Perroteau C, Moore N. Effectiveness and Safety of Rivaroxaban 15 or 20 mg Versus Vitamin K Antagonists in Nonvalvular Atrial Fibrillation. Stroke. 2019;50:2469–2476.
118. Fauchier L, Potpara T. Idarucizumab for Reversion of Anticoagulant Effect in Daily Practice. Thromb Haemost. 2020;120:5–7.
119. Boveda S, Garcia R, Defaye P, Piot O, Narayanan K, Barra S, Gras D, Providencia R, Algalarrondo V, Beganton F, Perier M-C, Jacob S, Bordachar P, Babuty D, Klug D, Leclercq C, Fauchier L, Sadoul N, Deharo J-C, Marijon E, DAI-PP investigators. Implantable cardioverter defibrillator therapy for primary prevention of sudden cardiac death in the real world: Main findings from the French multicentre DAI-PP programme (pilot phase). Arch Cardiovasc Dis. 2019;112:523–531.
120. Glikson M, Wolff R, Hindricks G, Mandrola J, Camm AJ, Lip GYH, Fauchier L, Betts TR, Lewalter T, Saw J, Tzikas A, Sternik L, Nietlispach F, Berti S, Sievert H, Bertog S, Meier B, ESC Scientific Document Group. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2019;

121. Lacour T, Bisson A, Bernard A, Fauchier L, Babuty D, Clementy N. How to upgrade a leadless pacemaker to cardiac resynchronization therapy. J Cardiovasc Electrophysiol. 2019;30:2578–2581.
122. Fauchier L, Blin P, Sacher F, Dureau-Pournin C, Bernard M-A, Lassalle R, Droz-Perroteau C, Dallongeville J, Moore N. Reduced dose of rivaroxaban and dabigatran vs. vitamin K antagonists in very elderly patients with atrial fibrillation in a nationwide cohort study. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2020;22:205–215.
123. Sunder S, Grammatico-Guillon L, Lemaignen A, Lacasse M, Gaborit C, Boutoille D, Tattevin P, Denes E, Guimard T, Dupont M, Fauchier L, Bernard L. Incidence, characteristics, and mortality of infective endocarditis in France in 2011. PloS One. 2019;14:e0223857.
124. Torp-Pedersen C, Goette A, Nielsen PB, Potpara T, Fauchier L, John Camm A, Arbelo E, Boriani G, Skjoeth F, Rumsfeld J, Masoudi F, Guo Y, Joung B, Refaat MM, Kim Y-H, Albert CM, Piccini J, Avezum A, Lip GYH, ESC Scientific Document Group. “Real-world” observational studies in arrhythmia research: data sources, methodology, and interpretation. A position document from European Heart Rhythm Association (EHRA), endorsed by Heart Rhythm Society (HRS), Asia-Pacific HRS (APHRS), and Latin America HRS (LAHRS). Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2019;
125. Maury P, Mansourati J, Fauchier L, Waintraub X, Boveda S, Sacher F. Management of sustained arrhythmias for patients with cardiogenic shock in intensive cardiac care units. Arch Cardiovasc Dis. 2019;112:781–791.